Jemperli Demonstrates Sustained Complete Responses in Rectal Cancer Study

GSK announced positive interim results from its AZUR-1 trial, showing Jemperli achieved sustained clinical complete responses in patients with a specific type of locally advanced rectal cancer. These findings suggest the immunotherapy could potentially reduce or eliminate the need for traditional treatments like chemotherapy, radiation, and surgery for some individuals. This marks a promising development in oncology, offering new treatment possibilities.